Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
复制标题
DOI：
10.3324/haematol.2010.030882
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Blade, Joan
中科院分区：
文献类型：
--
作者：
Fernandez de Larrea, Carlos;Tovar, Natalia;Blade, Joan
寡克隆带的出现与多发性骨髓瘤自体干细胞移植后的良好结局相关。本研究的目的是确定33例接受细胞毒性药物（n=18，54.5%）或新诱导方案（n= 15，45.4%）治疗后达到完全缓解的多发性骨髓瘤患者免疫球蛋白寡克隆性的患病率。11例（33.3%）出现寡克隆带。在用新药物治疗的组中，在60%（9/15）的患者中观察到这种寡克隆免疫应答，而在给予细胞毒性治疗的患者中仅观察到11.1%（2/18）（P=0.003）。这是第一份报告显示了不同频率的寡克隆体液反应的患者在完全缓解后实现常规细胞毒治疗与诱导纳入新的药物。这种差异可能是由于与使用新药相关的更高的抗肿瘤作用，更强的免疫重建，或两者兼而有之。
The emergence of oligoclonal bands is associated with a favorable outcome after autologous stem cell transplantation in multiple myeloma. The aim of this study was to determine the prevalence of immunoglobulin oligoclonality in 33 patients with multiple myeloma in complete remission achieved with primary therapy with either cytotoxic agents (n=18, 54.5%) or new induction regimens incorporating novel drugs (n=15, 45.4%). Eleven patients (33.3%) developed oligoclonal bands. In the group treated with novel agents, this oligoclonal immune response was observed in 60% (9 of 15) of the patients versus only 11.1% (2 of 18) of those given cytotoxic therapy (P=0.003). This is the first report showing a different frequency of oligoclonal humoral response in patients in complete remission achieved after conventional cytotoxic therapy versus induction incorporating novel agents. This difference could be due to a higher antitumor effect associated with the use of novel drugs, a stronger immune reconstitution, or both.